Orietta Picconi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8917336/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer, 2005, 41, 45-60.	1.3	1,024
2	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	1.4	172
3	Living with Psoriasis: Prevalence of Shame, Anger, Worry, and Problems in Daily Activities and Social Life. Acta Dermato-Venereologica, 2012, 92, 299-303.	0.6	132
4	Evidence for the Association of Human Papillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals. Archives of Dermatology, 2003, 139, 890-4.	1.7	109
5	Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART. PLoS ONE, 2010, 5, e13540.	1.1	94
6	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77.	1.4	89
7	HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies. PLoS ONE, 2012, 7, e48781.	1.1	56
8	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology, 2015, 12, 33.	0.9	55
9	Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	1.1	53
10	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	0.9	48
11	Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq1 1 0.	.78143814 rg	gB 4 \$Overloc
12	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	0.9	33
13	Development of the Italian Version of the National Institutes of Health Stroke Scale. Stroke, 2009, 40, 2557-2559.	1.0	27
14	Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Frontiers in Immunology, 2019, 10, 233.	2.2	23
15	BDNF Val66Met polymorphism and brain volumes in multiple sclerosis. Neurological Sciences, 2011, 32, 117-123.	0.9	21
16	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opinion on Biological Therapy, 2015, 15, 13-29.	1.4	19
17	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines, 2019, 7, 99.	2.1	14
18	The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Experimental Hematology, 2017, 50, 53-76.	0.2	12

ORIETTA PICCONI

#	Article	IF	CITATIONS
19	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. Expert Review of Vaccines, 2020, 19, 71-84.	2.0	12
20	HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. International Journal of Molecular Sciences, 2021, 22, 317.	1.8	12
21	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing—remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77.	1.5	11
22	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	0.8	11
23	Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART EBioMedicine, 2021, 66, 103306.	2.7	11
24	Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. Journal of Translational Medicine, 2011, 9, 42.	1.8	10
25	Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy. Journal of Personalized Medicine, 2021, 11, 756.	1.1	10
26	A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients. European Review for Medical and Pharmacological Sciences, 2021, 25, 3316-3324.	0.5	10
27	Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive) Tj ETQq1 1 (0.78 43 514 rg	gBT9/Overloc
28	High HIV-1 diversity in immigrants resident in Italy (2008–2017). Scientific Reports, 2020, 10, 3226.	1.6	8
29	Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. Frontiers in Oncology, 2019, 9, 1245.	1.3	6
30	New insights into pathogenesis point to HIV-1 Tat as a key vaccine target. Archives of Virology, 2021, 166, 2955-2974.	0.9	6
31	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. Molecular Cancer Therapeutics, 2020, 19, 2476-2489.	1.9	5
32	Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study. Journal of Dermatological Treatment, 2016, 27, 399-405.	1.1	4
33	"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies― Expert Review of Vaccines, 2017, 17, 1-12.	2.0	4
34	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. PLoS ONE, 2014, 9, e95183.	1.1	3
35	CALR resets the stress-response of erythroid cells and this function is impaired by CALR and JAK2 mutations alike in MPN. Experimental Hematology, 2016, 44, S70.	0.2	0
36	Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. Blood, 2016, 128, 399-399.	0.6	0

#	Article	IF	CITATIONS
37	The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. Blood, 2016, 128, 545-545.	0.6	0
38	Kaposi's Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies. International Journal of Molecular Sciences, 2022, 23, 2081.	1.8	0
39	Building up a collaborative network for the surveillance of HIV genetic diversity in Italy. A pilot study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 321-6.	0.2	0